-
公开(公告)号：EP2349484A2
公开(公告)日：2011-08-03
申请号：EP09780542.8
申请日：2009-07-14
申请人： Novartis AG
IPC分类号： A61P3/10 , C07D277/46 , C07D213/75 , C07D231/40 , C07D401/12 , C07D413/12
CPC分类号： C07D249/14 , C07D401/02 , C07D401/12 , C07D403/12 , C07D405/12 , C07D413/12
摘要： The invention relates to compounds of formula (I): where A is an optionally substituted heteroaryl, useful for treating disorders mediated by acyl coA- diacylglycerol acyl transferase 1 (DGAT1),
e.g. metabolic disorders. The invention also provides methods of treating such disorders, and compounds and compositions
etc. for their treatment.-
2.发明公开OXADIAZOLE- AND OXAZOLE-SUBSTITUTED BENZIMIDAZOLE- AND INDOLE-DERIVATIVES AS DGAT1 INHIBITORS 有权恶二唑和恶唑取代的苯并咪唑和吲哚衍生物作为DGAT1抑制剂的
公开(公告)号：EP2205595A1
公开(公告)日：2010-07-14
申请号：EP08804779.0
申请日：2008-09-26
申请人： Novartis AG
IPC分类号： C07D413/04 , C07D413/14 , A61K31/42 , A61K31/4245 , A61K31/44 , A61P3/00
CPC分类号： C07D413/04 , C07D413/14
摘要： The present invention provides oxadiazolyl- substituted benzimidazole- and idole-derivates that are useful for treating conditions or disorders associated with DGAT1 activity in animals, particularly humans.
-
公开(公告)号：EP2004607A2
公开(公告)日：2008-12-24
申请号：EP07754311.4
申请日：2007-03-28
申请人： NOVARTIS AG , Novartis Pharma GmbH
IPC分类号： C07D213/74 , C07D213/75 , C07D213/81 , C07D213/82 , C07D237/20 , C07D239/42 , C07D263/48 , C07D277/42 , C07D401/10 , C07D401/12 , C07D401/14 , C07D405/12 , C07D413/10 , A61K31/44
CPC分类号： C07D413/10 , A61K31/421 , A61K31/426 , A61K31/4418 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/50 , A61K31/501 , A61K31/505 , A61K31/506 , A61K45/06 , C07D213/72 , C07D213/73 , C07D213/74 , C07D213/76 , C07D237/20 , C07D239/42 , C07D263/48 , C07D277/42 , C07D401/12 , C07D401/14 , C07D413/14
摘要： The present invention provides organic compounds of the following structure; A-L1-B-C-D-L2-E that are useful for treating or preventing conditions or disorders associated with DGAT1 activity in animals, particularly humans.
-
4.发明授权OXADIAZOLE- AND OXAZOLE-SUBSTITUTED BENZIMIDAZOLE- AND INDOLE-DERIVATIVES AS DGAT1 INHIBITORS 有权恶二唑和恶唑取代的苯并咪唑和吲哚衍生物作为DGAT1抑制剂的
公开(公告)号：EP2205595B1
公开(公告)日：2014-09-10
申请号：EP08804779.0
申请日：2008-09-26
申请人： Novartis AG
IPC分类号： C07D413/04 , C07D413/14 , A61K31/42 , A61K31/4245 , A61K31/44 , A61P3/00
CPC分类号： C07D413/04 , C07D413/14
-
5.发明授权(4-(4-[6-(trifluoromethyl-pyridin-3-ylamino)-N-containing-heteroaryl]-phenyl)-cyclohexyl)-acetic acid derivatives and pharmaceutical uses thereof 有权（4-（4- [6-（三氟甲基 - 吡啶-3-基氨基）-N-含有杂芳基] - 苯基） - 环己基）乙酸衍生物及其药物应用
公开(公告)号：EP2004607B1
公开(公告)日：2011-10-19
申请号：EP07754311.4
申请日：2007-03-28
申请人： Novartis AG
IPC分类号： C07D213/74 , C07D213/75 , C07D213/81 , C07D213/82 , C07D237/20 , C07D239/42 , C07D263/48 , C07D277/42 , C07D401/10 , C07D401/12 , C07D401/14 , C07D405/12 , C07D413/10 , A61K31/44
CPC分类号： C07D413/10 , A61K31/421 , A61K31/426 , A61K31/4418 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/50 , A61K31/501 , A61K31/505 , A61K31/506 , A61K45/06 , C07D213/72 , C07D213/73 , C07D213/74 , C07D213/76 , C07D237/20 , C07D239/42 , C07D263/48 , C07D277/42 , C07D401/12 , C07D401/14 , C07D413/14
摘要： The present invention provides organic compounds of the following structure; A-L1-B-C-D-L2-E that are useful for treating or preventing conditions or disorders associated with DGAT1 activity in animals, particularly humans.
-
-
-
-
搜索结果
5 条记录 (耗时 0.01 秒)
